Analyst Price Targets — FATE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 14, 2026 12:19 pm | — | Piper Sandler | $8.00 | $2.57 | TheFly | Fate Therapeutics price target raised to $8 from $6 at Piper Sandler |
| August 14, 2026 10:27 am | — | Wells Fargo | $3.50 | $2.52 | TheFly | Fate Therapeutics price target raised to $3.50 from $2.50 at Wells Fargo |
| June 8, 2026 10:58 am | Debjit Chattopadhyay | H.C. Wainwright | $7.00 | $1.98 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Fate Therapeutics (FATE) |
| May 19, 2026 7:14 pm | — | Jefferies | $4.00 | $1.89 | TheFly | Fate Therapeutics assumed with a Buy at Jefferies |
| March 6, 2025 11:51 am | — | Stifel Nicolaus | $3.00 | $1.04 | TheFly | Fate Therapeutics price target lowered to $3 from $5 at Stifel |
| November 13, 2024 1:53 pm | Etzer Darout | BMO Capital | $5.00 | $3.37 | StreetInsider | Fate Therapeutics (FATE) PT Lowered to $5 at BMO Capital |
| August 14, 2024 8:37 am | Benjamin Burnett | Stifel Nicolaus | $5.00 | $3.27 | StreetInsider | Fate Therapeutics (FATE) PT Lowered to $5 at Stifel |
| June 17, 2024 3:50 am | Edward Tenthoff | Piper Sandler | $6.00 | $3.61 | StreetInsider | Piper Sandler Upgrades Fate Therapeutics (FATE) to Overweight |
| May 16, 2024 6:44 am | Debjit Chattopadhyay | H.C. Wainwright | $5.00 | $4.24 | StreetInsider | Fate Therapeutics (FATE) PT Lowered to $5 at H.C. Wainwright |
| May 10, 2024 8:14 am | Edward Tenthoff | Piper Sandler | $4.00 | $3.88 | StreetInsider | Fate Therapeutics (FATE) PT Lowered to $4 at Piper Sandler |
Latest News for FATE
Fate Therapeutics has initiated the phase 2 RECLAIM-LN trial of FT819 in lupus nephritis, dosing the first patient in an outpatient setting. FATE plans to open 20 trial sites by the end of 2026 and expects interim analysis data from multiple patients in H2'27, potentially accelerating enrollment. Phase 1 data for FT819 showed reductions in disease activity in systemic lupus erythematosus, including in patients with…
First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites
Fate Therapeutics (FATE) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.29 per share a year ago.
First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated as an outpatient with same-day discharge
Sen. Cynthia Lummis, R-Wyo., discusses the expected CLARITY Act vote, the budget agenda before recess, Congress' August checklist and the Democratic Party's direction after Tuesday's primaries on ‘Mornings with Maria.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for FATE.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.